Sino Biological COVID-19

Research Solutions for Coronavirus – Sino Biological

SARS-CoV-2 (2019-nCoV) Detection Kits, Antibodies and Proteins

The newly identified coronavirus, SARS-CoV-2 (2019-nCoV), has led to pneumonia (COVID-19) that sickened over 240,000 people worldwide. SARS-CoV-2 belongs to the Betacoronavirus Genus, which also includes SARS CoV (2003) and MERS CoV (2012). Same as all other coronaviruses, the genome of SARS-CoV-2 (2019-nCoV) encodes the spike protein, the envelope protein, the membrane protein, and the nucleocapsid protein.
The spike protein (S-protein) mediates receptor binding and membrane fusion. Spike protein contains two subunits, S1 and S2. S1 contains a receptor binding domain (RBD), which is responsible for recognizing and binding with the cell surface receptor. S2 subunit is the “stem” of the structure, which contains other basic elements needed for the membrane fusion. The spike protein is the common target for neutralizing antibodies and vaccines. It’s been reported that SARS-CoV-2 (2019-nCoV) (ref.) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. Indeed, the recombinant Spike protein can bind with recombinant ACE2 protein.
The Nucleocapsid Protein (N-protein) is the most abundant protein in coronavirus. The N-protein is a highly immunogenic phosphoprotein, and it is normally very conserved. The N protein of coronavirus is often used as a marker in diagnostic assays.
To aid the efforts of developing vaccines and neutralizing antibodies against this virus, Sino Biological Inc. has developed a panel of research reagents for SARS-CoV-2, including recombinant antigens (the N protein, S protein, the S1 and S2 subunits of the S protein, and the RBD domain of the S proteins), antibodies, antigen detection kits and genes.

SARS-CoV-2 Antigens

All coronaviruses share very similar structures.

The viral genome encodes several proteins of unique functions, S protein

N protein

HE protein

papain-like proteases

M protein.

The two antigens of main pharmaceutical interest are the S (spike) protein and the N protein.

  • The N (nucleocapsid) protein is often conserved, which can be used as a diagnostic marker.
  • The Spike protein is mainly responsible for receptor binding, and is a common target for vaccines and antibodies. The size of the abundantly N-glycosylated S protein varies greatly between CoV species

The spike protein is particularly important as its interaction with the host cell receptor is the pivotal step during the infection. Different viruses may utilize different surface receptor for binding. The HCOV- NL63, SARS-COV, and the new SARS-COV-2 viruses all use the ACE2 receptor, while the MERS-COV virus selectively binds with the DPP4 receptor. The HCOV-229E virus targets APN receptor. The rest two common coronavirus, HKU1 and OC43 bind with O-ac Sia.

Spike Protein

The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays a key role in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell

Nucleocapsid Protein

The N protein constitutes the only protein present in the nucleocapsid. It is composed of two separate domains, an N-terminal and a C-terminal domains both capable of binding viral RNA in vitro

N protein is also heavily phosphorylated and binds to the viral genome

N protein also binds nsp3, a key component of replicase-transcriptase complex , and the M protein and subsequently packages the encapsidated genome into viral particles.

Angiotensin-converting enzyme 2 (ACE2)

Angiotensin-converting enzyme 2 (ACE2) is a membrane receptor expressed on the surface of airway epithelial cells.

The interaction between the viral spike protein and the ACE2 receptor is mediated by the RBD domain of the spike protein, and is believed to be the pivotal event in the membrane fusion process.

It’s been shown that SARS-COV-2 also uses ACE2 as the receptor for host cell entry. This finding suggests that blocking the interaction between the S protein and ACE2 is a valid approach to prevent or treat coronavirus infection.

Expression Systems – SARS-CoV-2

Mammalian cells CHO, HEK293

  • Protein folding
  • Post-translational modification
  • Flexible and rapid production of proteins.
  • Lower production yield than bacterial systems
  • Higher cost than bacterial systems
  • Complex culture media

Insect cells expression systems

  • Robust
  • Simple culture media
  • High expression levels
  • Able to perform a variety of post-translational modifications similar to mammalian cells

Bacterial Systems

  • High protein expression yield
  • Most economical
  • No disulfite bonds
  • Additional modifications are required post production

Tags

IgG-Fc-tag (mFc = mouse IgG – rFc = rabbit IgG)

  • allows for rapid and simple detection of protein expression by ELISA
  • allows for simple affinity purification of the Fc-tagged protein by protein A, protein G, and protein L affinity purification resins.
  • increases protein expression yield.

His Tag

  • 6xHis-tag is one of the simplest and most widely used purification tags
  • The his-tag has a high affinity for metal ions  Ni2+or Co2+immobilized on beads or a resin for such as IMAC columns
N SARS-CoV-2 (2019-nCoV) Nucleocapsid-His Protein 40588-V08B Expressed in Insect cell
S1 SARS-CoV-2 (2019-nCoV) Spike S1-His Protein 40591-V08B Expressed in HEK293 cell, bind with ACE2
S1 SARS-CoV-2 (2019-nCoV) Spike S1-His Protein 40591-V08B1 Expressed in Insect cell, bind with ACE2
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-mFc Protein 40592-V05H Expressed in HEK293 cell, bind with ACE2
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-Fc Protein 40592-V02H Expressed in HEK293 cell, bind with ACE2
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-rFc Protein 40592-V31H Expressed in HEK293 cell, bind with ACE2
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein, Biotinylated 40592-V08B-B Expressed in Insect cell
S2 SARS-CoV-2 (2019-nCoV) Spike S2-mFc Protein 40592-V05H Expressed in HEK293 cell
S1+S2 SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Protein 40589-V08B1 Expressed in Insect cell, bind with ACE2
S1 SARS-CoV-2 (2019-nCoV) Spike S1-mFc Protein 40591-V05H1 Expressed in HEK293 cell, bind with ACE2
S1 SARS-CoV-2 (2019-nCoV) Spike S1-Fc Protein 40591-V02H Expressed in HEK293 cell, bind with ACE2
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein 40592-V08B Expressed in Insect cell, bind with ACE2
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein 40592-V08H Expressed in HEK293 cell, bind with ACE2
RBD SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein,Biotinylated 40592-V08H-B Expressed in HEK293 cell
S2 SARS-CoV-2 (2019-nCoV) Spike S2 ECD-His Protein 40590-V08B Expressed in Insect cell
Plpro SARS-CoV-2 (2019-nCoV) Plpro-His protein 40593-V07E Expressed in E.coli cell

SARS-CoV-2 Spike Mutant Proteins

Three fast-spreading new variants of SARS-CoV-2 virus have emerged in recent months: the U.K. variant B.1.1.7, the Brazil variant P.1, and the South Africa variant B.1.351.

A subset of the mutations identified in the RBD domain of the spike protein occurs in more than one strain, although the three variants are believed to be independently evolved. These convergent mutations, specifically, the N501Y (shared by all three, 40592-V08H82) and E484K (shared between B.1.351 and P.1, 40592-V08H84), are of high interest because they may be the cause of the increased transmissibility.

The mutations in these strains also occur in the nucleocapsid protein, which is commonly used as the biomarker in rapid antigen tests. It’s critical to assess whether the current commercial antigen tests can detect the mutated N proteins with the same sensitivity and specificity as their WT counterpart.

Sino Biological has developed a panel of recombinant RBD/Spike and nucleocapsid protein variants carrying the aforementioned mutations as below:

Recombinant Mutants from the U.K. Variant | B.1.1.7

Catalogue Antigen Mutation
40592-V08H82 RBD N501Y
40592-V08H82-B RBD-Biotinylated N501Y
40591-V08H7 S1 HV69-70 deletion, N501Y, D614G
40591-V08H12 S1 H69del, V70del, Y144del, N501Y, A570D, D614G, P681H
40588-V07E7 N D3L, R203K, G204R, S235F
40588-V07E8 N D3L, S235F
40589-V08B6 S-ECD H69del, V70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H

Recombinant Mutants from the South Africa Variant | B.1.351

Catalogue Antigen Mutation
40592-V08H82 RBD N501Y
40592-V08H84 RBD E484K
40592-V08H59 RBD K417N
40592-V08H85 RBD K417N, E484K, N501Y
40591-V08H10 S1 K417N, E484K, N501Y, D614G

Recombinant Mutants from the Brazil Variant | P.1

Catalogue Antigen Mutation
40592-V08H82 RBD N501Y
40592-V08H84 RBD E484K
40592-V08H86 RBD K417T, E484K, N501Y

Recombinant Mutants from the Denmark Mink Variant

Catalogue Antigen Mutation
40592-V08H80 RBD Y453F
40591-V08H8 S1 ΔH69/ΔV70, Y453F, D614G
40592-V08H86 RBD K417T, E484K, N501Y

High Frequency Mutation of Nucleocapsid

Catalogue Antigen Mutation
40588-V07E1 N R203K, G204R
40588-V07E2 N P13L
40588-V07E3 N S194L
40588-V07E4 N I292T

Conserved Domain of Nucleocapsid from SARS-CoV-2

Catalogue Antigen Mutation
40588-V07E5 N-CTD CTD
40588-V07E10 N-NTD NTD

SARS-CoV-2 Nucleocapsid Mutant

P13L
40588-V07E2
S194L
40588-V07E3
R203K, G204R
40588-V07E1
I292T
40588-V07E4
D3L, R203K, G204R, S235F
40588-V07E7
D3L, S235F
40588-V07E8

SARS-CoV-2 S1+S2 ECD Mutant

HV69-70 deletion, D614G, D796H
40589-V08B5
HV69-70 deletion, Y144 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
40589-V08B6
SARS-CoV-2 Spike RBD Mutant
P337S F338L V341I F342L A344S A348S
A352S N354D S359N V367F (mFc Tag)  V367F N370S
A372S A372T F377L K378N K378R P384L
T385A T393P V395I D405V, Q414A E406Q
R408I Q409E Q414R Q414E K417N A435S
W436R N439K N440K K444R V445F G446V
G446S L452R Y453F L455F F456L F456E
K458R K458Q E471Q I472V G476S S477R
S477I S477N T478I P479S N481D G482S
V483A V483I E484K E484Q G485S F486S
N487R F490L F490S S494P P499R N501Y
V503F Y505C Y508H A520V A520S P521S
P521R A522V A522S K417N, E484K, N501Y
40592-V08H85
K417T, E484K, N501Y
40592-V08H86

SARS-CoV-2 Spike S1 Mutant

HV69-70 deletion, Y144 deletion, N501Y, A570D, D614G, P681H
40591-V08H12
HV69-70 deletion, Y453F, D614G
40591-V08H8
HV69-70 deletion, N501Y, D614G
40591-V08H7
L18F, D614G
40591-V08H6
T20N, D614G
40591-V08H5
A222V, D614G
40591-V08H4
N234Q
40591-V08H11
K417N, E484K, N501Y, D614G
40591-V08H10
D614G
40591-V08H3
D614G
40591-V02H3
HV69-70 deletion, N439K, D614G
40591-V08H9
E780Q
40590-V02H1

SARS-CoV-2 Spike S1+S2 ECD Mutant

R683A, R685A, F817P, A892P, A899P, A942P, K986P, V987P
40589-V08H4

Resource for Studying the U.K. Variant

Catalogue  Antigen  Mutation 
40592-V08H82 RBD  N501Y 
40591-V08H7 S1  HV69-70 deletion, N501Y, D614G 
40591-V08H12 S1  H69del, V70del, Y144del, N501Y, A570D, D614G, P681H 

Recombinant Spike N501Y Mutant
Cat#: 40592-V08H82
Activity: Bind with ACE2

An unprecedented mink cull has been ordered in Denmark amid the outbreak of SARS-CoV-2 in these farmed animals. The plan was announced after scientists discovered a widespread Y453F mutation in the spike protein, that has been passed from animal to humans.

This mutation is of particular concern, because it occurs at a conservative domain of the receptor binding domain (RBD) directly involved in ACE2 binding. Results from some preliminary studies suggest the Y453F mutation affects the ability of the Spike protein to bind with ACE2, while others demonstrate that the mutated spike can escape from detection from a commercial anti-S antibody.

Although there is still no clear evidence indicating this mutation, or any other mutation like the popular D614G, has any clinical significance, the characteristics of the mutations need to be thoroughly investigated in the context of vaccine and antibody therapy.

Sino Biological has launched the recombinant Y453F RBD protein. This product is the newest addition to a large library of recombinant spike variants (full list here). These proteins can be used to evaluate the efficacy of the antibodies and vaccination.

SARS-CoV-2 Antibodies

Cat# Antigen Description Type
40588-T62 Nucleocapsid SARS-CoV-2 (2019-nCoV) Nucleocapsid Antibody Rabbit PAb
40143-R001 Nucleocapsid SARS-CoV/SARS-CoV-2 Nucleocapsid Antibody Rabbit MAb
40143-MM05 Nucleocapsid SARS-CoV/SARS-CoV-2 Nucleocapsid Antibody Mouse MAb
40143-R019 Nucleocapsid SARS-CoV-2 (2019-nCoV) Nucleocapsid Antibody Rabbit MAb
40143-MM08 Nucleocapsid SARS-CoV/SARS-CoV-2 Nucleocapsid Antibody Mouse MAb
40143-R040 Nucleocapsid SARS-CoV/SARS-CoV-2 Nucleocapsid Antibody Rabbit MAb
40143-R004 Nucleocapsid SARS-CoV/SARS-CoV-2 Nucleocapsid Antibody Rabbit MAb
40150-R007 Spike SARS-CoV-2 (2019-nCoV) Spike S1 Antibody Rabbit MAb
40150-D006 Spike SARS-CoV/SARS-CoV-2 Spike Antibody Chimeric MAb
40150-D004 Spike SARS-CoV/SARS-CoV-2 Spike antibody Chimeric MAb
40150-D003 Spike SARS-CoV/SARS-CoV-2 Spike antibody Chimeric MAb
40150-D005 Spike SARS-CoV/SARS-CoV-2 Spike antibody Chimeric MAb
40150-D002 Spike SARS-CoV/SARS-CoV-2 Spike antibody Chimeric MAb
40150-D001 Spike SARS-CoV/SARS-CoV-2 Spike antibody Chimeric MAb
40590-D001 Spike S2 SARS-CoV-2 (2019-nCoV) Spike S2 Antibody, Chimeric Mab Chimeric Mab
40592-T62 Spike SARS-CoV-2 (2019-nCoV) Spike RBD Antibody Rabbit PAb
40590-T62 Spike SARS-CoV-2 (2019-nCoV) Spike S2 Antibody Rabbit PAb

Validated Applications

IF (40150-R007) – Pseudovirus Validated

SARS-CoV-2 Spike in ACE2-overexpressed 293T cells, infected (left) or noninfected (right) by 2019-nCOV pseudovirus

WB (40143-MM05)

1-2: SARS-CoV N Protein
3-4: 2019-nCoV N Protein

IHC (40143-R019)

Renal tissue from COVID-19 Patient. N antigens in kidney tubules is validated by IHC

Catalogue
Species
Antigen
Type
Description
SARS-CoV-2
S RBD
Rabbit PAb
WB, ELISA, IHC-PF CM, ICC/IF, IP
SARS-CoV-2
Nucleocapsid
Rabbit PAb
WB, ELISA, IHC-PF CM, ICC/IF, IP
SARS-CoV-2
S2 subunit
Rabbit PAb
WB, ELISA, IHC-PF CM, ICC/IF, IP
SARS-CoV
Nucleocapsid
Rabbit PAb
Has cross-reactivity in ELISA with SARS-CoV-2 N Protein (Cat# 40588-V08B).
SARS-CoV
Spike
Rabbit PAb
Has cross-reactivity in ELISA and WB with SARS-CoV-2 S1 (Cat# 40591-V08H) and S-RBD (Cat# 40592-V05H)

Sars-CoV-2 Neutralising antibodies

Cat # 40591-MM43 40592-MM57 40592-R001
Description Anti-Spike S1Anti-Spike RBDAnti-Spike RBD
Type Mouse MAbMouse MAbRabbit MAb
Ig Type Mouse IgG1Mouse IgG2bRabbit IgG
Application Neutralization, ELISANeutralization, ELISANeutralization, ELISA

Neutralization Activity Assay
Neutralizing antibodies can effectively inhibit the infection of SARS-CoV-2 Spike pseudovirus on ACE2 overexpression 293T cells.

S1 Neutralizing Antibody

Conc. (µg/mL)Inhibition%
10096.39%
1094.57%
142.24%
0.1-5.53%

RBD Neutralizing Antibody 

Conc. (µg/mL)Inhibition%
10095.51%
1093.32%
175.69%
0.110.11%

RBD Neutralizing Antibody Rabbit MAb

Conc. (µg/mL)Inhibition%
10099.56%
499.9%
0.1659.29%
0.0325.59%

Competitive-ELISA Assay
Neutralizing ability was detected by SARS-CoV-2 Inhibitor Screening ELISA Kit (Catalog# KIT001) using competitive ELISA.

S1 Neutralizing Antibody

The IC50 is typically 0.857 nM

RBD Neutralizing Antibody

The IC50 is typically 3.694 nM

RBD Neutralizing Antibody Rabbit MAb

The IC50 is typically 0.066 nM

Specificity Assay

SARS-CoV-2 shares 80% sequence identity to the 2003 SARS-CoV. Hence, antibodies raised against SARS-CoV-2 antigens often shows various degree of cross-reactivity with the corresponding antigens of 2003 SARS-CoV. On the other hand, the similarities between SARS-CoV-2 and other members of human coronavirus are very limited. The following two clones of anti-spike antibodies have been tested against all seven coronavirus, and are shown to be specific to SARS-CoV-2 spike.

The reactivity of the antibodies against the known coronavirus is assessed in ELISA. The reactivity (OD450) is illustrated in the figure below.

S1 Neutralizing Antibody

RBD Neutralizing Antibody

Inihibitor Screening ELISA kits

Cat # Product Name
KIT001 SARS-CoV-2 (2019-nCoV) Inhibitor Screening ELISA Kit Competitive ELISA

Antibody Titer Assay Kits

Cat # Product Name
KIT002 SARS-CoV-2 (2019-nCoV) Spike RBD Antibody Titer Assay Kit Indirect ELISA kit
KIT003 SARS-CoV-2 (2019-nCoV) Spike S1 Antibody Titer Assay Kit Indirect ELISA kit
KIT004 SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD Antibody Titer Assay Kit Indirect ELISA kit

The S and N detection kits employ a standard sandwich ELISA, allowing rapid quantification of the N and S antigens.

  • All antibodies used in the kits are in-house developed monoclonal antibodies, ensuring batch-to-batch consistency.
  • These assays may be used to quantify antigens on the surface of SARS-CoV-2 and/or pseudovirus, as well as antigens expressed recombinantly.

2019-nCoV N Detection Kit
(KIT40588)

Sino Biological and Nanommune (Irvine, California) jointly developed the coronavirus antigen array. These arrays are constructed by printing recombinant antigens on a nitrocellulose-coated membrane. It can analyze serum antibodies against 65 antigens from 23 types of viruses known to cause respiratory tract infections, including SARS-COV-2 and the other six coronaviruses. The array is specifically designed for high throughput serological surveillance studies.

Catalogue

Description Species Tag Vector
VG40588-UT CoV Nucleocapsid 2019-nCoV 2019-nCoV No Tag Expression
VG40589-UT CoV spike 2019-nCoV 2019-nCoV No Tag Expression
VG40592-UT CoV spike 2019-nCoV 2019-nCoV No Tag Expression
VG40590-UT CoV spike 2019-nCoV 2019-nCoV No Tag Expression
VG40591-UT CoV spike 2019-nCoV 2019-nCoV No Tag Expression
VG40596-UT CoV Hemagglutinin esterase 2019-nCoV No Tag Expression
VG40598-UT CoV Membrane 2019-nCoV No Tag Expression
VG40599-UT CoV NSP10 2019-nCoV No Tag Expression
VG40594-UT CoV 3CLpro / 3C-like protease 2019-nCoV No Tag Expression
VG40597-UT CoV Envelope 2019-nCoV No Tag Expression
VG40593-UT CoV NSP3 2019-nCoV No Tag Expression

cDNA ORF clones expression plasmids

  • Sino Biological provides ready-to-use expression ORF clones without subcloning. The expression ORF clones can be use for transfecting immediately.
  • Codon Optimized clones for high expression, no tag
  • Datasheet contains complete information on on plasmid, gene and quality control

THE COMPLETE GUIDE TO SELECTING THE PROPER ANTIBODIES FOR YOUR COVID-19 STUDY

The ongoing COVID-19 pandemics has sickened 3.6 million people around the world, claiming over 250,000 lives. To address this global public health crisis, unprecedented efforts are being made to study the culprit virus, SARS-CoV-2. The biomedical community are working to develop rapid diagnostic reagents, vaccines, and therapies against this virus.

To support these studies, Sino Biological has developed a large collection of antibodies against different antigens of SARS-CoV-2. These antibodies can be used to detect and/or neutralize the virus in a variety of assays  including ELISA, western blot, Immunofluorescent staining, Immunohistochemistry, SPR (Biacore and Octet), pseudovirus infection, and potentially in vivo animal studies.

This guide covers all available SARS-CoV-2 antibodies offered by Sino Biological. The readers can find technical information about their specificity and sensitivity, cross-reactivity, neutralizing potential, and their validated applications. The overarching goal for this guide is to help the readers to choose appropriate antibodies for their own experiments.

Same as all other coronaviruses, the genome of SARS-CoV-2 (2019-nCoV) encodes the spike protein, the envelope protein, the non-structure proteins including the proteases and methyltransferases, the membrane protein, and the nucleocapsid protein.

1

The spike protein (S-protein) is the common target for neutralizing antibodies and vaccines. Spike protein contains two subunits, S1 and S2. S1 contains a receptor binding domain (RBD), which is responsible for recognizing and binding with the cell surface receptor ACE2. S2 subunit contains other basic elements needed for the membrane fusion.

3

The Nucleocapsid Protein (N-protein) is a highly immunogenic phosphoprotein, and it is normally very conserved. The SARS-CoV-2 N protein is often used as a marker in diagnostic assays.

5

The papain-like protease (PlPro) is a protease. It mediates the post-translational processing of other non-structural proteins like replicase polyprotein. PlPro, and 3CLPro. PlPro is a target for antiviral drug development.

4

The methyltransferase is a non-structural protein. Methyltransferase mediates the methylation of the viral RNA, which may help the virus evade the host immune system. Methyltransferase inhibitor may work as an anti-viral treatment.

6

Angiotensin-converting enzyme 2 (ACE2) binds with the Spike protein of coronaviruses  SARS-CoV  and  HCoV-NL63. This interaction is mediated by the RBD domain of the spike protein, and is believed to be the pivotal event in the membrane fusion process.

ELSIA Antibody Pairs

Pairs Ⅰ

Cat # 40143-R004 (Capture)
Description Anti-Nucleocapsid
Type Rabbit MAb
Ig Type Rabbit IgG
Cat # 40143-R040 (Detection)
Description Anti-Nucleocapsid
Type Rabbit MAb
Ig Type Rabbit IgG

Pairs ⅠⅠ

Cat # 40143-MM05 (Capture)
Description Anti-Nucleocapsid
Type Mouse MAb
Ig Type Mouse IgG
Cat # 40143-R001 (Detection)
Description Anti-Nucleocapsid
Type Rabbit MAb
Ig Type Rabbit IgG

Western Blot Antibodies

Cat # 40143-R019
Description Anti-Nucleocapsid
Type Rabbit MAb
Ig Type Rabbit IgG

FULL LIST OF ANTI-NUCLEOCAPSID ANTIBODIES

Cat # Description Type Ig Type
40143-R001 Anti-Nucleocapsid Rabbit MAb Rabbit IgG
40143-R040 Anti-Nucleocapsid Rabbit MAb Rabbit IgG
40143-R004 Anti-Nucleocapsid Rabbit MAb Rabbit IgG
40588-R0004 Anti-Nucleocapsid Rabbit MAb Rabbit IgG
40143-R019 Anti-Nucleocapsid Rabbit MAb Rabbit IgG
40143-MM05 Anti-Nucleocapsid Mouse MAb Mouse IgG1
40143-MM08 Anti-Nucleocapsid Mouse MAb Mouse IgG1
40588-T62 Anti-Nucleocapsid Rabbit PAb Rabbit IgG

ELSIA Antibody Pairs

Pairs Ⅰ

Cat # 40150-D001 (Capture)
Description Anti-Spike RBD
Type Chimeric MAb
Ig Type mouse v domain / human IgG1
Cat # 40150-D003 (Detection)
Description Anti-Spike RBD
Type Chimeric MAb
Ig Type mouse v domain / human IgG1

Pairs ⅠⅠ

Cat # 40150-D004 (Detection)
Description Anti-Spike RBD
Type Chimeric MAb
Ig Type mouse v domain / human IgG1
Cat # 40150-D002 (Capture)
Description Anti-Spike RBD
Type Chimeric MAb
Ig Type mouse v domain / human IgG1

Neutralization Antibodies

Cat # 40591-MM43
Description Anti-Spike S1
Type Mouse MAb
Ig Type Mouse IgG1
Cat # 40591-MM57
Description Anti-Spike RBD
Type Chimeric MAb
Ig Type Mouse IgG2b

IF Antibodies

Cat # 40150-R007
Description Anti-Spike S1
Type Rabbit MAb
Ig Type Rabbit IgG

High Affinity Antibodies

Cat # 40150-D005
Description Anti-Spike RBD
Type Chimeric MAb
Ig Type mouse v domain / human IgG1

Antibodies against the S2 Protein

Cat # 40590-D001
Description Anti-Spike S2
Type Chimeric MAb
Ig Type mouse v domain / human IgG1

This is a chimeric antibody specifically recognizing the S2 domain of SARS-CoV-2. The specificity assay is assessed in ELISA which shows no cross-reactivity with SARS-CoV-2 S1, RBD or MERS-CoV S2.

FULL LIST OF ANTI-SPIKE ANTIBODIES

Cat # Description Type Ig Type
40591-MM43 Anti-Spike S1 Mouse Mab,Neutralizing Antibody Mouse IgG1
40150-R007 Anti-Spike S1 Rabbit MAb Rabbit IgG
40150-D001 Anti-Spike S1 Chimeric MAb mouse v domain / human IgG1
40150-D002 Anti-Spike S1 Chimeric MAb mouse v domain / human IgG1
40150-D003 Anti-Spike S1 Chimeric MAb mouse v domain / human IgG1
40150-D004 Anti-Spike S1 Chimeric MAb mouse v domain / human IgG1
40150-D005 Anti-Spike S1 Chimeric MAb mouse v domain / human IgG1
40150-D006 Anti-Spike S1 Chimeric MAb mouse v domain / human IgG1
40592-MM57 Anti-Spike RBD Mouse Mab,Neutralizing Antibody Mouse IgG2b
40592-T62 Anti-Spike RBD Rabbit MAb Rabbit IgG
40590-D001 Anti-Spike S2 Chimeric MAb mouse v domain / human IgG1
40590-T62 Anti-Spike S2 Rabbit MAb Rabbit IgG
40589-T62 Anti-Spike Rabbit MAb Rabbit IgG
Cat # 40592-MM57
Description Spike RBD Antibody
Type Mouse MAb
Ig Type Monoclonal Mouse IgG2b
Application ELISA, Neutralization
Cat # 40591-MM43
Description Spike S1 Antibody
Type Mouse MAb
Ig Type Monoclonal Mouse IgG1
Application ELISA, Neutralization

The reactivity of the antibodies against the known coronavirus is assessed in ELISA. The reactivity (OD450) is illustrated in the figure below.

SARS-CoV-2 shares 80% sequence identity to the 2003 SARS-CoV. Hence, antibodies raised against SARS-CoV-2 antigens often shows various degree of cross-reactivity with the corresponding antigens of 2003 SARS-CoV. On the other hand, the similarities between SARS-CoV-2 and other members of human coronavirus are very limited. The following two clones of anti-spike antibodies have been tested against all seven coronavirus, and are shown to be specific to SARS-CoV-2 spike.

SUPPORT

outstanding technical support

PRODUCT

we offer a full product guarantee

DELIVERY

we offer free delivery to UK universities and non profit organisations